Loading

Please wait...

Hyqvia

Generic Name: hyaluronidase and immune globulin (HYE al ure ON i dase and i MUNE GLOB ue lin)
Brand Name: Hyqvia
Physician reviewed Hyqvia patient information - includes Hyqvia description, dosage and directions.
  • Prescription Settings
  • X

Prices and coupons of Hyqvia

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Hyaluronidase is a genetically designed protein used as an aid in helping your body absorb other injected medications. Immune globulin is a sterilized solution made from human plasma. It contains the antibodies to help your body protect itself against infection from various diseases. Hyqvia are given together to treat primary immunodeficiency in adults. Hyqvia may also be used for purposes not listed in this medication guide. You should not use Hyqvia if you have ever had a severe allergic Reaction to an immune globulin, or if you have immune globulin A (IgA) deficiency with antibody to IgA. Learn more

Hyqvia Side Effects

Hyqvia Side Effects

Note: This document contains side effect information about hyaluronidase / immune globulin. Some of the dosage forms listed on this page may not apply to the brand name Hyqvia.

In Summary

More frequent side effects include: fever, nausea, and vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to hyaluronidase/immune globulin: subcutaneous solution

Warning

Subcutaneous route (Kit)

Thrombosis may occur with immune globulin/recombinant human hyaluronidase in patients with or without known risk factors. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Adequate hydration prior to administration is recommended. Administer at the minimum dose and infusion rate practicable in patients at risk of thrombosis. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Along with its needed effects, hyaluronidase / immune globulin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking hyaluronidase / immune globulin:

More common

  • Fever

Some side effects of hyaluronidase / immune globulin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Headache
  • nausea
  • red streaks on the skin
  • swelling, tenderness, or pain at the injection site
  • unusual tiredness or weakness
  • vomiting

Less common

  • Itching, redness, swelling, discomfort, or pain at the infusion site

For Healthcare Professionals

Applies to hyaluronidase / immune globulin: subcutaneous solution

General

The most common adverse events were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.

Local

Very common (10% or more): Local reaction (51.9%)

Frequency not reported: Local pain and swelling, discomfort/pain, erythema, pruritus

Nervous system

Very common (10% or more): Headache (21%), fatigue (11.1%)

Postmarketing reports: Transient ischemic attack, tremor, burning sensation, cerebrovascular accident, coma, seizures, loss of consciousness

Immunologic

Very common (10% or more): Antibodies to recombinant human hyaluronidase (18%)

Other

Very common (10% or more): Systemic adverse reaction (67.9%)

Common (1% to 10%): Pyrexia

Frequency not reported: Fever, back injury, transient swelling from abdominal infusion site to genitalia

Postmarketing reports: Edema, rigors

Gastrointestinal

Common (1% to 10%): Nausea, vomiting

Postmarketing reports: Abdominal pain

Hematologic

Frequency not reported: Acute intravascular hemolysis

Postmarketing reports: Leukopenia, pancytopenia

Renal

Frequency not reported: Acute renal dysfunction/failure

Cardiovascular

Postmarketing reports: Hypotension, hypertension, myocardial infarction, chest pain, cardiac arrest, vascular collapse

Respiratory

Postmarketing reports: Pulmonary edema, dyspnea, oxygen saturation decreased, cyanosis, hypoxemia, bronchospasm, apnea, acute respiratory distress syndrome (ARDS)

Dermatologic

Postmarketing reports: Hyperhidrosis, allergic dermatitis, bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson Syndrome

Hepatic

Postmarketing reports: Hepatic dysfunction

Psychiatric

Postmarketing reports: Anxiety, insomnia

Musculoskeletal

Postmarketing reports: Back pain

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Hyqvia (www.drugs.com/mtm/hyqvia.html).